LG Chem Ltd. is slated for exclusive talks with Seoul-based Glenwood Private Equity to sell off its in vitro diagnostics business, according to biopharmaceutical industry sources on Wednesday.
The South Korean conglomerate LG Group's unit and lead financial advisor Samjong KPMG tapped the PE firm as a preferred bidder on May 2. The deal is estimated to reach 100 billion-150 billion won ($74.8 million-$112.2 million), sources said.
Glenwood, specializing in carve-out strategies that partially divest non-core businesses or subsidiaries, competed with local peers such as STIC Investments, Korea Investment Private Equity and EUM Private Equity in a bidding round last month.
LG Chem, running petrochemicals, advanced materials and life science divisions, started producing diagnostics reagents in 1992. Its mainstay products include rapid antigen test (RAT) kits and polymerase chain reaction (PCR) equipment for allergy and viral respiratory infection tests.
The company won a license to import in vitro diagnostics devices in 2006 and was approved to domestically manufacture such tests in 2013.
MORE FOCUS ON NEW DRUG DEVELOPMENT
LG Chem has considered an exit from the diagnostics market as it has lost competitiveness in the fast-changing industry since the pandemic. While it launched COVID-19 RATs and PCR reagents in May 2021 and July 2022, respectively, local rivals such as Seegene Inc. and SD Biosensor Inc. earlier swept the market by launching the test kits immediately after the outbreak of the pandemic.
The life science division will focus on the production of new drugs such as anti-cancer treatments, as well as invest 2 trillion won in research and development of such medicines between 2023 and 2027.
It completed a $571 million purchase of US biotech AVEO Pharmaceuticals Inc. in January to strengthen its anti-cancer drug portfolio and accelerate its foray into the US.
The firm also constructed Korea’s first pharmaceuticals plant dedicated to clinical trials in February. The new facilities in Osong, North Chungcheon Province, manufacture both biologics and chemical drugs.
Write to Jeong-Min Nam and Ji-Eun Ha at peux@hankyung.com
Jihyun Kim edited this article.
South Korean chemical company LG Chem Ltd. has announced the release of a new diabetes combination drug, Zemidapa Tab, set to launch on Apr. 8. The drug is based on the active ingredient gemigliptin, known as Zemiglo, and dapagliflozin, both leading products in their respective markets of DP
LG Chem diagnostic reagent factory in Osong, Korea (Courtesy of LG Chem) LG Chem Ltd. is considering an exit from the in-vitro diagnostics market to focus more on novel drug development as it lagged its smaller local rivals in riding the COVID-19 diagnostic reagent boom. According to sourc
LG Chem completed the $571 million purchase of the US biotech firm AVEO Pharmaceuticals in January LG Chem Ltd. has built South Korea’s first pharmaceutical plant dedicated to clinical trials, which the company expects to speed up its medicine development by directly handling drug candida
LG Chem Vice Chair Shin Hak-cheol (fourth from left) and AVEO CEO Michael Bailey (fourth from right) on Jan. 19 (Courtesy of LG Chem) LG Chem Ltd. is set to complete its $571 million purchase of the US biotech firm AVEO Pharmaceuticals Inc. on Friday, which would strengthen its anti-cancer drug